Gradient Investments’s Myriad Genetics MYGN Stock Holding History

Gradient Investments’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-420	Closed	-$5K	–	1186
2020 Q2	$5K	Hold	420	–	–	﹤0.01%	747
2020 Q1	$6K	Sell	420 -200	-32%	-$4.22K	﹤0.01%	752
2019 Q4	$17K	Hold	620	–	–	﹤0.01%	592
2019 Q3	$18K	Buy	620 +200	+48%	+$5.83K	﹤0.01%	546
2019 Q2	$12K	Hold	420	–	–	﹤0.01%	611
2019 Q1	$14K	Hold	420	–	–	﹤0.01%	505
2018 Q4	$12K	Hold	420	–	–	﹤0.01%	548
2018 Q3	$19K	Hold	420	–	–	﹤0.01%	511
2018 Q2	$16K	Hold	420	–	–	﹤0.01%	526
2018 Q1	$12K	Hold	420	–	–	﹤0.01%	595
2017 Q4	$14K	Buy	+420	New	+$14.2K	﹤0.01%	533
2017 Q3	–	Sell	-420	Closed	-$11K	–	533
2017 Q2	$11K	Hold	420	–	–	﹤0.01%	467
2017 Q1	$8K	Hold	420	–	–	﹤0.01%	546
2016 Q4	$7K	Hold	420	–	–	﹤0.01%	501
2016 Q3	$9K	Hold	420	–	–	﹤0.01%	469
2016 Q2	$13K	Buy	+420	New	+$14.6K	﹤0.01%	395

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Gradient Investments's MYGN Position: Q3 2020 in Review

Gradient Investments sold out of Myriad Genetics (MYGN) in Q3 2020, closing a stake of 420 shares — an estimated $5K sold.

Gradient Investments first reported a position in MYGN in Q2 2016 and held it in 16 quarters. The position peaked at $19K in Q3 2018. 192 funds tracked by Wall St. Rank hold MYGN as of Q3 2020.

Gradient Investments reported no remaining Myriad Genetics position as of Q3 2020 after selling out during the quarter.
Gradient Investments sold 420 Myriad Genetics shares in Q3 2020, an estimated $5K.
Gradient Investments first reported a position in Myriad Genetics in Q2 2016 and held it in 16 quarters.
Gradient Investments's Myriad Genetics position peaked at $19K in Q3 2018.
192 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2020.

Based on Gradient Investments's 13F filing for Q3 2020, filed 6 Oct 2020.